Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2022 (fiscal second quarter and first half of fiscal 2023). The unaudited statements are consolidated. Propanc is a development-stage biotechnology company; its lead candidate, PRP, is preclinical and intended for cancer treatment.
Financial performance and position
| Metric | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $608,004 | $1,180,834 | $403,467 / $889,497 |
| Operating loss | $608,004 | $1,180,834 | $403,467 / $889,497 |
| Net loss | $485,418 | $1,102,713 | $799,977 / $1,290,635 |
| Net loss available to common stockholders | $504,740 | $1,511,270 | $893,375 / $1,498,877 |
| Net cash used in operating activities | Not presented by quarter | $734,542 | $711,093 |
Balance sheet at Dec. 31, 2022: Cash was $24,476; current assets were $54,226; current liabilities were $2,992,554; working-capital deficit was $2,938,328; total liabilities were $3,023,439; and stockholders’ deficit was $2,915,417. The filing reports no revenue, so operating margins are not meaningful.
Debt and liquidity: Current liabilities included $633,740 of convertible notes, net of discounts and premiums; a $72,404 note payable, net; and a $65,280 past-due Crown Bridge loan, in addition to substantial payables, accrued expenses and employee-benefit liabilities. Cash increased from $4,067 at June 30 to $24,476, principally as financing proceeds of $744,219 exceeded operating cash use. Management says available cash is insufficient to meet obligations over the next 12 months and that continued operations depend on additional financing.
Changes versus comparable periods
- First-half operating expenses rose to $1.18 million from $889,497. Administration expense increased to $990,752 from $777,904, and R&D expense increased to $176,203 from $97,307, primarily reflecting research collaborations.
- First-half net loss narrowed to $1.10 million from $1.29 million, partly reflecting derivative fair-value gains and other non-operating items. The loss available to common stockholders increased slightly to $1.51 million from $1.50 million, including a $408,557 deemed dividend related to warrant repricing.
- Operating cash use increased to $734,542 from $711,093. Financing provided $744,219, including proceeds from notes, warrant exercises, and stock sales.
- Common shares outstanding increased from 220.4 million at June 30 to 1.246 billion at December 31, primarily through debt conversions, warrant exercises, and issuances for services and financing. The filing reports 1.764 billion shares outstanding as of February 9, 2023.
Outlook, commentary, and material risks
- Going concern: The filing states that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from issuance. Management is seeking additional debt or equity financing; there is no assurance it will be available on acceptable terms. The financial statements include no adjustments for the outcome of this uncertainty.
- Financing and dilution: The company relies on financing, including convertible notes with variable-price conversion features, discounts, default interest and penalty provisions. The Coventry note carries $125,000 principal and guaranteed interest, with monthly payments scheduled to begin in March 2023. The company also disclosed equity-line agreements of up to $5 million each with Dutchess and Coventry, subject to conditions including effective resale registration statements.
- Defaults and maturities: The Crown Bridge loan was past due and in default at quarter-end; it carried a 15% default rate. Management said it was discussing an extension with the lender. Several other notes had 2023 maturities, and certain financing agreements contain significant default penalties or conversion terms.
- Development: PRP remains preclinical. The company reported progress in synthetic trypsinogen production and research on the tumor microenvironment, and reported patent allowances and a broad patent portfolio. These are development updates, not evidence of regulatory approval or commercial sales.
- Other risks and unusual items: COVID-19 effects remain uncertain. Cash deposits in Australian banks are uninsured. The filing reports no material pending litigation known to the company, but discloses a previously accrued $30,000 IRS penalty plus interest for late historical filings. Related-party arrangements include office leasing and executive employment compensation.
- Controls: Management concluded disclosure controls were not effective at December 31, 2022, citing material weaknesses including no written control procedures, inadequate segregation of duties, no audit committee, and insufficient financial-reporting review and US GAAP expertise.
- Guidance: The filing provides no numerical revenue, earnings, or cash-flow guidance.
Important facts for investors to verify
- Current cash, near-term obligations, the status of financing efforts, and whether the going-concern uncertainty has changed.
- Outstanding debt by lender, maturity, default status, accrued interest, and the terms and consequences of variable-price conversions.
- Share-count changes and potential dilution from convertible debt, warrants, reserved shares, and equity-line facilities; reconcile the quarter-end count with the February 9 count.
- The filing’s conversion disclosures: the financial-statement notes describe $158,500 principal converted from October through December, while the unregistered-sales section reports $485,700 for that period. Clarify the period and amounts underlying this difference.
- PRP’s development stage, clinical and regulatory milestones, and whether reported research or patent developments translate into validated progress toward commercialization.
- Whether management implements corrective actions for the disclosed material weaknesses and whether future filings report effective controls.